Background: There is no consistent evidence regarding the prognostic value of metabolic syndrome (MS) in predicting all-cause mortality and coronary heart disease (CHD) risk among type 2 diabetic patients. We sought to investigate whether individual or various combinations of MS components have a different predictive value than the presence of MS in this setting.

Methods: Six hundred type 2 diabetic patients (mean age 60.4+/-9 years, 54% males) without known CHD were prospectively followed-up for a mean period of 10.06 years. The presence of MS was examined using the National Cholesterol Education Program (NCEP) definition. Statistical analyses were performed using Kaplan-Meier estimator and Cox proportional Hazard models.

Results: MS was present in 62.4% of the patients while 142 died during follow-up. Significant predictors for all-cause mortality were the presence of MS (HR 1.75), sex (HR 1.69), age (HR 1.09), and diabetes duration (HR 1.02). Regarding CHD incidents, HDL (HR 0.98), systolic blood pressure (HR 1.01), sex (HR 2.05), and total cholesterol (HR 1.005) were significant predictors while the presence of MS was not. Subjects fulfilling the triad consisting of diabetes, hypertension, and low HDL or the combination of diabetes, hypertension, low HDL, and high triglyceride levels had the highest probability for developing CHD events (HR 1.79, 1.73, respectively).

Conclusions: The presence of MS in type 2 diabetic patients without known CHD reduces the 10-year survival while specific combinations of its components have different impact on CHD risk.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2006.09.019DOI Listing

Publication Analysis

Top Keywords

type diabetic
16
diabetic patients
16
all-cause mortality
12
metabolic syndrome
8
predictors all-cause
8
mortality coronary
8
coronary heart
8
heart disease
8
chd risk
8
combinations components
8

Similar Publications

Background: Adolescent diabetes is one of the major public health problems worldwide. This study aims to estimate the burden of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in adolescents from 1990 to 2021, and to predict diabetes prevalence through 2030.

Methods: We extracted epidemiologic data from the Global Burden of Disease (GBD) on T1DM and T2DM among adolescents aged 10-24 years in 204 countries and territories worldwide.

View Article and Find Full Text PDF

Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity.

Diabetol Metab Syndr

January 2025

Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No.666 Shengli Road, Nantong, 226001, China.

Background: Increased glucagon levels are now recognized as a pathophysiological adaptation to counteract overnutrition in type 2 diabetes (T2D). This study aimed to elucidate the role of glucagon in peripheral nerve function in patients with T2D with different body mass indices (BMIs).

Methods: We consecutively enrolled 174 individuals with T2D and obesity (T2D/OB, BMI ≥ 28 kg/m), and 480 individuals with T2D and nonobesity (T2D/non-OB, BMI < 28 kg/m), all of whom underwent oral glucose tolerance tests to determine the area under the curve for glucagon (AUC).

View Article and Find Full Text PDF

Studies have shown that the prognosis of dental implant treatment in patients with diabetes is not as good as that in the non-diabetes population. The nerve plays a crucial role in bone metabolism, but the role and the mechanism of peripheral nerves in regulating peri-implant osteogenesis under Type 2 diabetes mellitus (T2DM) situation remains unclear. In this study, it was shown that high glucose-stimulated Schwann cells (SCs) inhibited peri-implant osteogenesis via their exosomes.

View Article and Find Full Text PDF

Background: The link between obesity and cardiometabolic risk has been well recognized. We investigated the association between body fat percentage (BF%), as an appropriate indicator of obesity, and prevalence of cardiometabolic diseases using baseline data of Fasa PERSIAN cohort study.

Methods: The cross-sectional study was performed on data obtained at the first phase of the Fasa cohort study in Iran (n = 4658: M/F: 2154/2504).

View Article and Find Full Text PDF

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.

BMC Cardiovasc Disord

January 2025

The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.

Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!